MeiraGTx (MGTX) announced a broad strategic collaboration in the area of ophthalmology with Eli Lilly (LLY). MeiraGTx will grant Lilly worldwide exclusive rights to its AAV-AIPL1 program for treatment of one of the most severe inherited retinopathies, Leber congenital amaurosis 4 owing to genetic deficiency of Aryl-hydrocarbon-interacting protein-like 1. Lilly will also receive worldwide exclusive access rights to MeiraGTx’s innovative gene therapy technologies for use in ophthalmology with certain targets named by Lilly, including novel intravitreal capsids developed in-house at MeiraGTx and bespoke promoters including AI-generated promoters for specific cells in the retina. MeiraGTx also grants Lilly certain rights to its proprietary riboswitch technology for use in gene editing in the eye. MeiraGTx’s riboswitch technology platform is broadly applicable to any therapeutic protein. It allows precise, titratable in-vivo production of the therapeutic protein or gene editing nuclease from a gene template controlled by oral dosing of a small molecule inducer.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGTX:
- MeiraGTx and Eli Lilly Collaborate on Genetic Medicines
- MeiraGTx’s Gene Therapy Study for Xerostomia: A Promising Update
- MeiraGTx’s Gene Therapy Trial: A Potential Game-Changer for Radiation-Induced Xerostomia
- MeiraGTx initiated with a Strong Buy at Raymond James
- MeiraGTx to present on genetic medicine, cell therapy at ESGCT 2025